Study S003229

A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of ZP7570 in Healthy Subjects

ClinicalTrials.gov record

Registration

Registration: NCT04612517
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: EARLY_PHASE1
Masking: TRIPLE
Status: COMPLETED
Enrollment: 40
Start: 2020-10-26
Primary completion: 2021-08-30
Lead sponsor: Zealand Pharma
Conditions: Healthy
Interventions: DRUG:ZP7570; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2019-001129-29; NIH:2019

Registered primary outcomes

Safety and Tolerability - Incidence of treatment emergent adverse events as assessed by type and severity [From time 0 to 51 days after first dosing (29 days after fourth dosing) ]]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.